Clinically, DYNLL1-AS1 elevation correlates with anti-PD-L1 resistance, CD8+ T cell depletion, and reduced survival, redefining PD-L1 regulation from tumor- centric to an EVs-mediated intercellular paradigm. This evidence concerns the gene CD8A and neoplasm.